← Leaderboards
Erik Pierstorff
O-Ray Pharma, Inc.
$2,278,637
Attributed
$3,024,870
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $839.1K · FY2012–18$1M$750K$500K$250K$0
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$3,024,870 · 5
By mechanism
R44$2,539,762 · 2
R43$485,108 · 3
Top collaborators
- William H Slattery3 shared
Most similar at O-Ray Pharma, Inc.
Same institution · by research overlap
- William H Slattery$3,101,465
- Matthew Ku$1,025,035
Others in their field
Top investigators on “Steroids”
- Leonardo Trasande · New York University School Of Medicine$51,045,834
- John C S Breitner · Johns Hopkins University$42,838,256
- Peter O Kohler · Oregon Health And Science University$38,512,009
- Janet T. Holbrook · Johns Hopkins University$38,100,099
- Bert W O'Malley · Baylor College Of Medicine$34,166,116
- Wanda Phipatanakul · Boston Children'S Hospital$25,025,564
Research focus
SteroidsDosePolymersSmall Business Innovation Research GrantScientistHearing ImpairmentOtologyLicensingResearch PersonnelImplantClinicProduct DevelopmentAnimal ModelAnti-InflammatoryDrug DevelopmentFutureImplantationLabyrinthDrug Delivery SystemsPharmaceutical PreparationsSafetySafety StudyAnti-Inflammatory AgentsCavia
Grant awards (7)
Inner ear therapeutics for sustained treatment of autoimmune inner ear disease$169,214
R43 · FY2018 · DC · contact PI
Prevention of Children's Tympanostomy Tube Otorrhea$567,267
R44 · FY2017 · DC · contact PI
Prevention of Children's Tympanostomy Tube Otorrhea$634,501
R44 · FY2016 · DC · contact PI
Sustained Release Inner Ear Delivery of Corticosteroid$498,847
R44 · FY2015 · DC
Intratympanic delivery of biologics for treatment of autoimmune inner ear disease$161,422
R43 · FY2015 · DC · contact PI
Sustained Release Inner Ear Delivery of Corticosteroid$839,147
R44 · FY2014 · DC
Ototoxicity protection with intratympanic steroid implant$154,472
R43 · FY2012 · DC · contact PI